Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALB-TRIAL
2022-501006-34-00Phase 3Withdrawn
- Sponsor
- Odense University Hospital, European Foundation For The Study Of Chronic Liver Failure
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised trial of human albumin in Cirrhosis (2 arms), sponsored by Odense University Hospital, European Foundation For The Study Of Chronic Liver Failure. Primary endpoint: Cumulative number of liver-related clinical outcomes. Planned start Sep 2022; status: withdrawn.
02
Drugs
human albumin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2022-501006-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501006-34-00.